Trial Profile
A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMCL-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2019
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
- 06 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.